Cardiome Pharma Corporation Культура компании

Dr. William L. Hunter, also known as Bill, M.D., Msc, BSc, has been the Chief Executive Officer and President at Cardiome Pharma Corp. since July 2012 and serves as its Managing director. Dr. Hunter serves as a Member of Angiotech Pharmaceuticals Inc.'s scientific and management teams. He serves as Senior Advisor of Bml Canada Limited and Advisor at Bioscience Managers Pty Ltd. He founded Angiotech Pharmaceuticals Inc. in 1992 and served as its Chief Executive Officer from 1997 to October 17, 2011 and President from September 2002 to October 17, 2011. He also served as a Senior Advisor at Rosetta Capital Limited. He served as an Interim Chief Executive Officer of Cardiome Pharma Corp. since July 2012. He served as the Chairman of Angiotech Pharmaceuticals Inc. from August 1998 to September 2002, Chief Scientific Officer from January 1997 to August 1998 and its Executive Director from June 10, 2004 to November 05, 2011. He served as the Chairman of Neuromed Pharmaceuticals Ltd. since July 25, 2007. He has been a Director of Cardiome Pharma Corp. since June 11, 2007 and CombinatoRx, Incorporated since December 2009. He has been an Independent Non Executive Director of Adherium Limited since December 17, 2015. He serves as a Non-Executive Director of Rex Bionics Plc. He served as Non Executive Director of Union MedTech Plc since July 16, 2012. Dr. Hunter served as Director of Angiotech Pharmaceuticals Inc. since November 1992 and Zalicus Inc. since December 2009. He served as an Independent Director of AnorMED Inc. since April, 21, 2006. He is active in the Science Council of British Columbia and serves as a Director of The Michael Smith Foundation for Health Research. He served as an Independent Director at EPIRUS Biopharmaceuticals, Inc. since December 2009 until July 25, 2016. He served as a Director of Neuromed Pharmaceuticals Ltd. since 2004. He served as a Director of Vigil Health Solutions Inc. He served as a Director of Aspreva International Ltd. (formerly Aspreva Pharmaceuticals Corporation) since June 2006, served on the Boards of Active Pass Pharmaceuticals Inc., Viewpoint Inc. and the Canadian Arthritis Network and served on the Steering Committee for BIO 2002. He serves as an Senior Advisor for the Biotechnology MBA Program at the University of Western Ontario's Ivey School of Business. He has co-authored many peer-reviewed publications and abstracts, funded research grants and 200 patents and patent applications since 1992. He has earned numerous awards including the 2002 BC Biotech Vision and Leadership Award, the 2001 Pacific Region Entrepreneur of the Year Award for Technology and Communications, British Columbia Science & Technology Award for Industrial Innovation, Business in Vancouver's Top 40 under 40, as well as the Caldwell Partners Canada's Top 40 under 40. He is honored with many awards including the 2006 Principal Award for Innovation from the Manning Foundation, the 2005 BC Innovation Council's Cecil Green Award for Science and Technology Entrepreneurship and the co-recipient of 2006 NSERC Synergy Awards for Innovation along with Dr. Helen Burt, recognizing the collaboration between the University of British Columbia and Angiotech. Dr. Hunter is honored with the 2005 Canadian Venture Capital Association's Entrepreneur of the Year. Dr. Hunter received his Bachelor of Science from McGill University, Montreal in 1985 and his Masters of Science with a focus on Angiogenesis and Doctor of Medicine Degree from the University of British Columbia in 1989 and 1992 respectively.

Mr. Hugues Sachot has been Chief Commercial Officer of Cardiome Pharma Corp. since May 16, 2017. Mr. Sachot served as Senior Vice President of Commercial at Cardiome Pharma Corp. from October 18, 2016 to May 16, 2017 and served as its Senior Vice President of Sales since March 2013. Mr. Sachot served as Vice President of Commercial at Angiotech. He served as Vice President of Sales & Marketing for the EMEA region and subsequently, worldwide at Angiotech Pharmaceuticals. Prior to Angiotech, Mr. Sachot worked for 15 years at Johnson & Johnson where he held several Sales and Marketing Director positions in Europe, including at J&J's subsidiaries, Ethicon Endo-Surgery, Biosense Webster and Cordis Corporation. Mr. Sachot has a B.A in economics, as well as a Master of Business Administration degree from the ESSEC-IMD Business School in Paris.

Mr. David D. McMasters, Esq., J.D., has been General Counsel of Cardiome Pharma Corp. since November 1, 2012. Mr. McMasters served as Senior Vice President of Legal of Angiotech Pharmaceuticals Inc. from January 2004 to July 12, 2011 and December 2000 to July 12, 2011 respectively. Mr. McMasters served as Vice President of Itellectual Property and General Counsel of Angiotech Pharmaceuticals Inc. from December 2000 to January, 2004. Prior to that, Mr. McMaster served as Managing Director and Chief Executive Officer of Seed Intellectual Property Law Group PLLC in 2000, Managing Partner, Seed and Berry from 1998 to 1999 and as Partner, Seed and Berry from 1995 to 1999. Mr. McMasters joined Angiotech Pharmaceuticals Inc. in December 2000 from one of the leading U.S. intellectual property law firms, Seed Intellectual Property Law Group (previously Seed and Berry), where he lastly served as its Managing Director and Chief Executive Officer. For over a decade with Seed, Mr. McMasters specialized in biotechnology and chemical patent matters as well as related litigation. was responsible for overseeing all legal matters pertaining to Angiotech including patent, copyright and intellectual property matters, as well as the coordination of any legal matters handled by outside counsel. He serves as a Director of Cardiome International AG. Mr. McMasters received his BSc in Microbiology and Immunology from the University of Washington and his J.D. from Northwestern University. Mr. McMasters is a member of the Washington State Bar and is registered to practise before the U.S. Patent and Trademark Office.

Ms. Sheila M. Grant, MBA, has been the Chief Operating Officer at Cardiome Pharma Corp. since March 26, 2013. Ms. Grant served as the Vice President of Product Development ??? Vernakalant at Cardiome Pharma Corp. since April 2005 until March 2013. Ms. Grant served as the Vice President of Commercial Affairs of Cardiome Pharma Corp. from August 15, 2003 to April 2005. Ms. Grant appointed as Director of Finance and Administration in May 1998 and re-titled as Director of Business and Clinical Development in June 2000. Ms. Grant also served as Cardiome Pharma Corp.'s Corporate Secretary from May 1997 to September 2002. She joined Cardiome Pharma Corp. in September 1996 as the Director of Business. Prior to joining Cardiome Pharma Corp., Ms. Grant acted as business consultant to De Novo Enzyme Corporation and Coopers & Lybrand. Ms. Grant also worked in research and development, production and quality assurance with Schering Agrochemicals U.K., Wellcome Biotechnologies U.K. and Serono Diagnostics U.K. respectively. Ms. Grant holds a B.Sc. (Hons) degree from the Essex University, U.K. and an MBA degree from Simon Fraser University.